Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 8/2020

01-08-2020 | Hashimoto Thyroiditis | Research Article

Expressions of IL-17 and TNF-α in patients with Hashimoto’s disease combined with thyroid cancer before and after surgery and their relationship with prognosis

Authors: N. Zhang, Q. Wang, Y. Tian, S. Xiong, G. Li, L. Xu

Published in: Clinical and Translational Oncology | Issue 8/2020

Login to get access

Abstract

Objective

This study aimed to investigate expressions and clinical significance of IL-17 and TNF-α after surgery in patients with Hashimoto’s disease (HD) combined with thyroid cancer (TC).

Patients and methods

From June 2010 to October 2012, 38 patients with HD combined with TC admitted to the oncology department of Tongji Hospital were selected as an experimental group, including three males and 35 females, aged 24–78 years. Forty adults undergoing physical examination during the same period were selected as a control group. All patients in the experimental group were given total endoscopic TC resection. Real-time fluorescence quantification (qRT-PCR) and enzyme-linked immunosorbent assay (ELISA) were used to detect the expression levels of serum IL-17 and TNF-α before and 14 days after surgery. Patients with HD combined with TC were divided into high and low expression groups according to the median values of preoperative IL-17 mRNA and TNF-α mRNA. The relationship between IL-17, TNF-α, and prognosis of patients was analyzed through K-M survival curve.

Results

The concentrations of IL-17 and TNF-α in serum were also higher than those in control group 14 days after surgery (p < 0.05). qRT-PCT showed that the relative expressions of IL-17 and TNF-α in serum 14 days after surgery were higher than those in control group (p < 0.05). According to the relative expression median of mRNA in IL-17 and TNF-α before surgery, they were divided into high and low expression groups. It was found that the survival rate of high expression groups of IL-17 and TNF-α was lower than that of low expression groups (IL-17, p = 0.028; TNF-α, p = 0.014).

Conclusions

The protein and mRNA of IL-17 and TNF-α in serum of HD patients with TC are higher than those of healthy control group. Expressions of IL-17 and TNF-α can be reduced by surgical resection of focal tissue. IL-17 and TNF-α may be used as potential prognostic indicators of HD patients with TC.
Literature
1.
Torimoto K, Okada Y, Nakayamada S, Kubo S, Tanaka Y. Anti-PD-1 antibody therapy induces Hashimoto’s disease with an increase in peripheral blood follicular helper T cells. Thyroid. 2017;27:1335–6.CrossRef
2.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRef
3.
Strickland KC, Howitt BE, Marqusee E, Alexander EK, Cibas ES, Krane JF, Barletta JA. The impact of noninvasive follicular variant of papillary thyroid carcinoma on rates of malignancy for fine-needle aspiration diagnostic categories. Thyroid. 2015;25:987–92.CrossRef
4.
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.CrossRef
5.
Mestman JH. Fetal hyperthyroidism resulted from TSI in a mother with Hashimoto’s hypothyroidism. Clin Thyroidol. 2017;29:32–4.CrossRef
6.
La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F, Negri E. Thyroid cancer mortality and incidence: a global overview. Int J Cancer. 2015;136:2187–95.CrossRef
7.
Boi F, Pani F, Calo PG, Lai ML, Mariotti S. High prevalence of papillary thyroid carcinoma in nodular Hashimoto’s thyroiditis at the first diagnosis and during the follow-up. J Endocrinol Investig. 2018;41:395–402.CrossRef
8.
9.
Akitsu A, Ishigame H, Kakuta S, Chung SH, Ikeda S, Shimizu K, Kubo S, Liu Y, Umemura M, Matsuzaki G, Yoshikai Y, Saijo S, Iwakura Y. IL-1 receptor antagonist-deficient mice develop autoimmune arthritis due to intrinsic activation of IL-17-producing CCR2+ Vγ6+ γδ T cells. Nat Commun. 2015;6:7464.CrossRef
10.
De Simone V, Franze E, Ronchetti G, Colantoni A, Fantini MC, Di Fusco D, Sica GS, Sileri P, MacDonald TT, Pallone F, Monteleone G, Stolfi C. Th17-type cytokines, IL-6 and TNF-α synergistically activate STAT3 and NF-kB to promote colorectal cancer cell growth. Oncogene. 2015;34:3493–503.CrossRef
11.
Wu P, Baker JR. Apoptosis in autoimmune thyroid disease. In: Rapoport B, McLachlan SM, editors. Graves’ disease. MA: Springer; 2000. pp. 107–126.
12.
Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRef
13.
Cancer Genome Atlas Program Office. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676–90.CrossRef
14.
Kim J, Bang Y, Lee WJ. Living near nuclear power plants and thyroid cancer risk: a systematic review and meta-analysis. Environ Int. 2016;87:42–8.CrossRef
15.
Zayed AA, Ali MK, Jaber OI, Suleiman MJ, Ashhab AA, Al Shweiat WM, Momani MS, Shomaf M, AbuRuz SM. Is Hashimoto’s thyroiditis a risk factor for medullary thyroid carcinoma? Our experience and a literature review. Endocrine. 2015;48:629–36.CrossRef
16.
Huang TC, Cheng YK, Chen TW, Hsu YC, Liu EW, Chen HH. A ‘silent’skull metastatic follicular thyroid carcinoma mimicking as a benign scalp tumor in a pregnant woman. Endocrinol Diabetes Metab Case Rep. 2017;2017:16.PubMedPubMedCentral
17.
Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014;170:R241–R252252.CrossRef
18.
Girardi FM, Barra MB, Zettler CG. Papillary thyroid carcinoma: does the association with Hashimoto’s thyroiditis affect the clinicopathological characteristics of the disease? Braz J Otorhinolaryngol. 2015;81:283–7.CrossRef
19.
Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, Moghaddam SJ, Dong C. T helper 17 cells play a critical pathogenic role in lung cancer. Proc Natl Acad Sci USA. 2014;111:5664–9.CrossRef
20.
Seguin L, Desgrosellier JS, Weis SM, Cheresh DA. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015;25:234–40.CrossRef
21.
Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE. IL-17-producing γδ T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345–8.CrossRef
22.
Bär E, Whitney PG, Moor K, Reis e Sousa C, LeibundGut-Landmann S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity. 2014;40:117–27.CrossRef
23.
Li D, Cai W, Gu R, Zhang Y, Zhang H, Tang K, Xu P, Katirai F, Shi W, Wang L, Huang T, Huang B. Th17 cell plays a role in the pathogenesis of Hashimoto’s thyroiditis in patients. Clin Immunol. 2013;149:411–20.CrossRef
24.
Jiang XL, Zhang H, Chen YL, Peng L. Expression of microRNA-221 and IL-17 in papillary thyroid carcinoma and correlation with clinicopathologic features. Zhonghua Bing Li Xue Za Zhi=Chin J Pathol. 2017;46:160–5.
25.
Kobawala TP, Trivedi TI, Gajjar KK, Patel DH, Patel GH, Ghosh NR. Significance of TNF-α and the adhesion molecules: l-selectin and VCAM-1 in papillary thyroid carcinoma. J Thyroid Res. 2016;2016:8143695.PubMedPubMedCentral
26.
Díez JJ, Hernanz A, Medina S, Bayón C, Iglesias P. Serum concentrations of tumour necrosis factor-alpha (TNF-α) and soluble TNF-α receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function. Clin Endocrinol. 2002;57:515–21.CrossRef
Metadata
Title
Expressions of IL-17 and TNF-α in patients with Hashimoto’s disease combined with thyroid cancer before and after surgery and their relationship with prognosis
Authors
N. Zhang
Q. Wang
Y. Tian
S. Xiong
G. Li
L. Xu
Publication date
01-08-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02253-1

Other articles of this Issue 8/2020

Clinical and Translational Oncology 8/2020 Go to the issue

Review Article

Organoid of ovarian cancer: genomic analysis and drug screening

Research Article

Whole-body MRI: a powerful alternative to bone scan for bone marrow staging without radiation and gadolinium enhancer

Research Article

Is one brachytherapy fraction of 7 Gy similar to more fractions after external beam irradiation in postoperative endometrial carcinoma?

Research Article

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Brief Research Article

Current functioning of cardio-oncology units in Spain

Research Article

A real-life analysis on the indications and prognostic relevance of perioperative chemotherapy in locally advanced resectable gastric adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits